Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
CDK4 is an essential insulin effector in adipocytes
Sylviane Lagarrigue, … , C. Ronald Kahn, Lluis Fajas
Sylviane Lagarrigue, … , C. Ronald Kahn, Lluis Fajas
Published December 14, 2015
Citation Information: J Clin Invest. 2016;126(1):335-348. https://doi.org/10.1172/JCI81480.
View: Text | PDF | Corrigendum | Retraction
Research Article Endocrinology Metabolism

CDK4 is an essential insulin effector in adipocytes

  • Text
  • PDF
Abstract

Insulin resistance is a fundamental pathogenic factor that characterizes various metabolic disorders, including obesity and type 2 diabetes. Adipose tissue contributes to the development of obesity-related insulin resistance through increased release of fatty acids, altered adipokine secretion, and/or macrophage infiltration and cytokine release. Here, we aimed to analyze the participation of the cyclin-dependent kinase 4 (CDK4) in adipose tissue biology. We determined that white adipose tissue (WAT) from CDK4-deficient mice exhibits impaired lipogenesis and increased lipolysis. Conversely, lipolysis was decreased and lipogenesis was increased in mice expressing a mutant hyperactive form of CDK4 (CDK4R24C). We performed a global kinome analysis and found that mice lacking Cdk4 had impaired insulin signaling in the adipose tissue. Interestingly, our results demonstrated that insulin activates the cyclin D3-CDK4 complex, which, in turn, phosphorylates the insulin receptor substrate 2 (IRS2) at the Ser 388, likely creating a positive feedback loop to maintain adipocyte insulin signaling. Furthermore, we found that CCND3 expression and IRS2 serine 388 phosphorylation are increased in human obese subjects. Together, our results demonstrate that CDK4 is a major regulator of insulin signaling in WAT.

Authors

Sylviane Lagarrigue, Isabel C. Lopez-Mejia, Pierre-Damien Denechaud, Xavier Escoté, Judit Castillo-Armengol, Veronica Jimenez, Carine Chavey, Albert Giralt, Qiuwen Lai, Lianjun Zhang, Laia Martinez-Carreres, Brigitte Delacuisine, Jean-Sébastien Annicotte, Emilie Blanchet, Sébastien Huré, Anna Abella, Francisco J. Tinahones, Joan Vendrell, Pierre Dubus, Fatima Bosch, C. Ronald Kahn, Lluis Fajas

×

Figure 1

Positive correlation between CDK4 activity and WAT mass.

Options: View larger image (or click on image) Download as PowerPoint
Positive correlation between CDK4 activity and WAT mass.
(A) Expression ...
(A) Expression levels of CCND1, CCND2, CCND3, CDK4, and CDK6 proteins in mouse eWAT, BAT, brain, muscle, heart, kidney, lung, spleen, and liver. Representative blot of several animals analyzed is shown. (B) CDK4 protein level in the SVF and mature adipocytes isolated from VAT. (C) Subcellular localization of CCND1, CCND2, CCND3, and CDK4 proteins in cytoplasm and nuclear fractions of eWAT and mature 3T3-L1 adipocytes. LMNA was used as a control for the nuclear fraction. (B and C) Representative blots out of 3 independent experiments are shown. (D and E) Body weight and percentage of fat mass of 20-week-old Cdk4+/+ and Cdk4nc mice (n = 9) (D) and 30-week-old Cdk4+/+ and Cdk4R24C/R24C mice (n = 8) (E) as obtained using EchoMRI technology. (F) H&E staining of eWAT sections from Cdk4+/+ (23 week old), Cdk4nc (29 week old), and Cdk4R24C/R24C (54 week old) mice. (G) Body weight, Δ to fat mass of 14- to 16-week-old Cdk4flox/flox mice infected with AAV8-mini/aP2-null (n = 5) or AAV8-mini/aP2-cre (n = 4) analyzed by EchoMRI technology (we show the difference between the percentage of fat before and the percentage of fat 3 weeks after infection). (H) H&E staining of eWAT sections from 16-to 18-week-old Cdk4flox/flox mice infected with AAV8-mini/aP2-null or AAV8-mini/aP2-cre. (I) Body weight and percentage of fat mass of 30-week-old E2f1+/+ (n = 4), Cdk4R24C/R24C E2f1+/+ (n = 6), and Cdk4R24C/R24C E2f1–/– mice (n = 12). (J) H&E staining of eWAT sections from 33-week-old E2f1+/+, Cdk4R24C/R24C E2f1+/+, and Cdk4R24C/R24C E2f1–/– mice. Statistically significant differences were determined with unpaired 2-tailed Student’s t tests (D, E, and G) or 1-way ANOVA followed by Tukey’s multiple comparisons test (I). *P < 0.05. Original magnification, ×100.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts